BioSig Technologies, Inc. (BSGM)

Beyond the Status Quo

As physician advocates, we develop technology that provides greater clarity and opens doors to ingenious treatment solutions for the most challenging arrhythmias. We collaborate with physicians, experts, and healthcare leaders to align on the advancements that can be realized in the field of electrophysiology.

We are driven by a commitment to provide innovative solutions that elevate the standard of care. Our engineers are constantly in search of what’s possible in signal acquisition and the field of electrophysiology, driving the evolution of our technology for the physicians we serve.

An Innovation in One of the Most Critical Areas of Electrophysiology

The PURE EP™ Platform applies a unique combination of hardware and software to accurately capture intracardiac signals with unprecedented clarity and precision. By viewing pure signals that are absent of saturation, interference, or noise from other medical equipment, physicians can respond to even the most complex cardiac arrhythmias with insight-based, highly targeted cardiac ablation procedures.

Discover the PURE EP™ Platform

MEETING THE NEED TO IMPROVE ARRHYTHMIA TREATMENT

"If we improve the fidelity of our [signal] recordings, we can potentially improve the efficiency and safety of our procedures. In that respect, the PURE EP™ System is really a breath of fresh air in this field."

- Hicham El Masry, M.D. (Mayo Clinic, Arizona)
Leveraging EGMs to Improve Efficacy, Safety of Ablation Kansas City Heart Rhythm Symposium (KCHRS) 2022

Discover BioSig

BioSig is on the leading edge of digital signal processing in healthcare. Join us on the front lines to unlock the future of cardiac treatment and help transform healthcare.

Join Our Team

Company

BioSig is an advanced signal processing company delivering unmatched accuracy and precision to intracardiac signal visualization, and enhancing the treatment of arrhythmias.

Learn more about BioSig

Leadership

By uniting the diverse talents and collective experiences of industry experts, we are determined to break down barriers and go beyond our comfort zone in pursuit of unconventional solutions that advance medical technology and make a lasting impact.

Careers

BioSig is on the leading edge of digital signal processing in healthcare. Join us on the front lines to unlock the future of cardiac treatment and help transform healthcare.

Join our team

Insights

With the superior, real-time visualization of arrhythmias, PURE EP™ is paving the way for personalized patient care and breakthrough innovations in the field of electrophysiology. View the latest cases, presentations, and papers.

News & Stories

BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market

March 26, 2025

Los Angeles, CA, March 26, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) ('BioSig' or the 'Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce that its common stock will continue trading on The Nasdaq Capital Market ('Nasdaq').

BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

November 13, 2024

Los Angeles, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ('BioSig' or 'Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced that it has received notice from the Nasdaq Listing Qualifications staff ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule").

BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel

October 22, 2024

Los Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) ('BioSig' or the 'Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company's common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities ('MVLS') requirement previously became non-compliant.

Delivering Superior Signal Clarity